PL4028002T3 - Przeciwnowotworowe połączenie chidamidu i celekoksybu - Google Patents
Przeciwnowotworowe połączenie chidamidu i celekoksybuInfo
- Publication number
- PL4028002T3 PL4028002T3 PL19944886.1T PL19944886T PL4028002T3 PL 4028002 T3 PL4028002 T3 PL 4028002T3 PL 19944886 T PL19944886 T PL 19944886T PL 4028002 T3 PL4028002 T3 PL 4028002T3
- Authority
- PL
- Poland
- Prior art keywords
- chidamide
- celecoxib
- cancer combination
- cancer
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2019/105421 WO2021046765A1 (en) | 2019-09-11 | 2019-09-11 | An anticancer combination of chidamide and celecoxib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4028002T3 true PL4028002T3 (pl) | 2026-03-30 |
Family
ID=74865995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19944886.1T PL4028002T3 (pl) | 2019-09-11 | 2019-09-11 | Przeciwnowotworowe połączenie chidamidu i celekoksybu |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4028002B1 (pl) |
| JP (2) | JP2022547555A (pl) |
| KR (1) | KR102908068B1 (pl) |
| CN (1) | CN114786672B (pl) |
| AU (1) | AU2019465985B2 (pl) |
| BR (1) | BR112022004471A2 (pl) |
| CA (1) | CA3153597A1 (pl) |
| ES (1) | ES3057788T3 (pl) |
| MX (1) | MX2022002856A (pl) |
| PL (1) | PL4028002T3 (pl) |
| WO (1) | WO2021046765A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115322171B (zh) * | 2022-08-30 | 2023-03-17 | 深圳微芯生物科技股份有限公司 | 一种trka(g667c)和flt3靶点抑制剂及其与西达本胺的组合物 |
| CN119431228B (zh) * | 2024-10-29 | 2025-08-12 | 成都苑东生物制药股份有限公司 | 西达本胺晶型i及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103833626B (zh) * | 2012-11-27 | 2015-11-25 | 深圳微芯生物科技有限责任公司 | 西达本胺的晶型及其制备方法与应用 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| IL264068B2 (en) * | 2018-01-05 | 2023-07-01 | Great Novel Therapeutics Biotech & Medicals Corp | Aggregate and pharmaceutical preparation containing an hdac inhibitor and an nsaid aggregate together with an immune checkpoint inhibitor for use in a method for removing immunosuppression in the microenvironment of a tumor or stimulating an immune system against cancer cells |
-
2019
- 2019-09-11 CN CN201980100308.4A patent/CN114786672B/zh active Active
- 2019-09-11 CA CA3153597A patent/CA3153597A1/en active Pending
- 2019-09-11 ES ES19944886T patent/ES3057788T3/es active Active
- 2019-09-11 MX MX2022002856A patent/MX2022002856A/es unknown
- 2019-09-11 BR BR112022004471A patent/BR112022004471A2/pt unknown
- 2019-09-11 AU AU2019465985A patent/AU2019465985B2/en active Active
- 2019-09-11 EP EP19944886.1A patent/EP4028002B1/en active Active
- 2019-09-11 WO PCT/CN2019/105421 patent/WO2021046765A1/en not_active Ceased
- 2019-09-11 PL PL19944886.1T patent/PL4028002T3/pl unknown
- 2019-09-11 JP JP2022515831A patent/JP2022547555A/ja active Pending
- 2019-09-11 KR KR1020227011577A patent/KR102908068B1/ko active Active
-
2024
- 2024-04-18 JP JP2024067413A patent/JP2024105304A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022004471A2 (pt) | 2022-05-31 |
| AU2019465985B2 (en) | 2024-05-02 |
| JP2024105304A (ja) | 2024-08-06 |
| KR102908068B1 (ko) | 2026-01-05 |
| EP4028002C0 (en) | 2025-12-17 |
| EP4028002A1 (en) | 2022-07-20 |
| CA3153597A1 (en) | 2021-03-18 |
| WO2021046765A1 (en) | 2021-03-18 |
| CN114786672A (zh) | 2022-07-22 |
| ES3057788T3 (en) | 2026-03-04 |
| MX2022002856A (es) | 2022-03-25 |
| AU2019465985A1 (en) | 2022-04-28 |
| EP4028002A4 (en) | 2023-06-14 |
| KR20220061179A (ko) | 2022-05-12 |
| EP4028002B1 (en) | 2025-12-17 |
| CN114786672B (zh) | 2024-07-12 |
| JP2022547555A (ja) | 2022-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL293377B1 (en) | Hsd17b13 variants and uses thereof | |
| IL282775A (en) | Selection of improved tumor reactive t-cells | |
| IL259102A (en) | Non-invasive physiological quantification of stress levels | |
| EP3874764A4 (en) | TEXT ANNOTATION OF ACOUSTIC EFFECTS | |
| EP3353156A4 (en) | AUTOPALMITOYLATION INHIBITORS OF THE TEAD TRANSCRIPTION FACTOR | |
| EP3746071A4 (en) | GCN2 INHIBITORS AND THEIR USES | |
| DK3595653T3 (da) | Sammensætninger af plinabulin og anvendelse heraf | |
| IL258997B (en) | Honey-cannabinoid therapeutic composition | |
| DK3283107T3 (da) | Sammensætninger omfattende en kombination af ipilimumab og nivolumab | |
| LT4331584T (lt) | Lanifibranoro deuterintų darinių terapietiniai naudojimai | |
| DK3713554T3 (da) | Doseringsanvisninger for vidofludimus til behandling af kroniske inflammatoriske og/eller autoimmunsygdomme | |
| PL3394259T3 (pl) | Kompozycje i sposoby zmniejszania ekspresji tau | |
| EP3314503A4 (en) | SIMULATION OF AN APPLICATION | |
| DK3182962T3 (da) | Compositions and uses of amidine derivatives | |
| PT3645518T (pt) | Síntese de omecamtiv mecarbil | |
| DK4335517T3 (da) | Indgivelse og dosering af diaminofenothiaziner | |
| JP2018172409A5 (ja) | 15−hepeを含む組成物および同組成物を使用する方法 | |
| DK3355041T3 (da) | Strækbar touchpad af den kapacitive type | |
| LT3448846T (lt) | Indazolų sintezė | |
| PL3411021T3 (pl) | Nowe zastosowanie kombinacji sakubitrylu i walsartanu | |
| IL281938A (en) | Stable semaglutide compositions and uses thereof | |
| HUE049331T2 (hu) | Indazolok szintézise | |
| SI3573620T1 (sl) | Sestavki za zdravljenje hipertenzije | |
| EP3589734A4 (en) | REGULATION OF GENE EXPRESSION BY CLIVING BY RNASE P MODULATED BY APTAMER | |
| DK3927899T3 (da) | Nedvibrering af funderinger |